All In Biotech

Drug Trial Radar · NCT07459556

A Prospective Study of Stapokibart Injection in Patients With Seasonal Allergic Rhinitis (SAR)

A Prospective Study of Stapokibart Injection in Patients With SAR

Last checked: Nov 19, 2026Latest source record: Mar 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Mar 2026

Primary completion

Dec 2027

Study completion Feb 2028

Sponsor

Sponsor type
Industry
First posted
Mar 9, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open label, prospective study to evaluate the safety of Stapokibart Injection in subjects with SAR.

Conditions

  • SAR

Interventions

  • StapokibartBiological

    subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence rate of adverse reactions (ADR).Time frame: From enrollment to the end of treatment at 10 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tongren Hospital, CMU

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.